The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday.